Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5202120
Max Phase: Preclinical
Molecular Formula: C18H28N8
Molecular Weight: 356.48
Associated Items:
ID: ALA5202120
Max Phase: Preclinical
Molecular Formula: C18H28N8
Molecular Weight: 356.48
Associated Items:
Canonical SMILES: Nc1nc(N)nc(NCCCCCN2CCN(c3ccccc3)CC2)n1
Standard InChI: InChI=1S/C18H28N8/c19-16-22-17(20)24-18(23-16)21-9-5-2-6-10-25-11-13-26(14-12-25)15-7-3-1-4-8-15/h1,3-4,7-8H,2,5-6,9-14H2,(H5,19,20,21,22,23,24)
Standard InChI Key: CEYHRGCVTQARPC-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 356.48 | Molecular Weight (Monoisotopic): 356.2437 | AlogP: 1.44 | #Rotatable Bonds: 8 |
Polar Surface Area: 109.22 | Molecular Species: BASE | HBA: 8 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.45 | CX LogP: 2.49 | CX LogD: -0.37 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.61 | Np Likeness Score: -1.49 |
1. Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J.. (2022) Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases., 227 [PMID:34710746] [10.1016/j.ejmech.2021.113931] |
Source(1):